https://www.avient.com/knowledge-base/article/four-ways-improve-surface-aesthetics-tpes
1.
https://www.avient.com/resource-center?document_type=62&page=1
This statement has been published in accordance with section 54(1) of the Modern Slavery Act 2015 and constitutes the second modern slavery and human trafficking statement of ColorMatrix Europe Limited (“ColorMatrix”) and covers the 2022 financial year.
https://www.avient.com/knowledge-base/article/injection-molding-mold-design?rtype[]=1164
Longer sprues may require more taper (3° - 5°), as shown in Figure 1.
The different sprue designs possible are shown in Figures 1 through 5.
1, 2 and 4
https://www.avient.com/investor-center/news/avient-announces-second-quarter-2023-results
Attachment 1
Special items (1)
1)
https://www.avient.com/investor-center/news/avient-announces-third-quarter-2023-results
Attachment 1
Special items (1)
1)
https://www.avient.com/investor-center/news/polyone-announces-second-quarter-2016-results
per share (see Attachment 1).
Attachment 1
Special items (1)
https://www.avient.com/products/advanced-composites/continuous-fiber-composite-tape-laminates-and-barstock/gordon-composites-thermoset-laminates-barstock
Get Help Now
+1-866-737-2066
https://www.avient.com/news/avient-feature-specialty-technologies-and-services-healthcare-mdm-west-2023
Like other Mevopur formulations, they are manufactured in dedicated ISO 13485 facilities and supported by testing to ISO 10993-1, USP, European Pharmacopeia, and ICH Q3D guidelines.
https://www.avient.com/company/policies-and-governance/colormatrix-europe-limited-modern-slavery-and-human-trafficking-statement-0
This statement has been published in accordance with section 54(1) of the Modern Slavery Act 2015 and constitutes the second modern slavery and human trafficking statement of ColorMatrix Europe Limited (“ColorMatrix”) and covers the 2022 financial year.
https://www.avient.com/resources/safety-data-sheets?page=4570
Shipment Notification - under "Material Header" MSDS - labeled as the "Product Number" (in Section 1)